Ⅲb及Ⅲc期结肠癌辅助化疗后行卡培他滨巩固化疗的临床
研究
张煜;李鸿雁;马力文
【期刊名称】《癌症进展》 【年(卷),期】2012(010)004
【摘要】Objective To observe the DFS (disease-free survival rale) of a group of posloperalive stage IIIb and IIIcrncolon cancer palients, who continued Lo Lake oral Capecilabine as consolidation chemolherapy after adjuvant chemothera-py. Methods 22 posloperalive slage IIIb and IIIc colon cancer patients treated in our hospital from June 2005 lo Septem-rnber 2008 were enrolled. After 3-6 months rest following 6-month rouline adjuvanl chemolherapy, they continued to take 6 cycles of oral Capecitabine as consolidation chemolherapy, then whose disease-free survival and related adverse effects during therapy were observed, DFS was calculated by Life Tables analysis.Results Using Capecitabine as consolidation chemolherapy in postoperalive stage IIIb and IIIc colon cancer patients is of high safely, with low recurrence and metastasis rales, and high disease-free survival rate, as the adverse effects are limited.Conclusion Postoperative IIIb and IIIc colon cancer patients receive oral Capecilabine as consolidation chemotherapy may improve disease-free survival rale, suggesting it is worthy of further and extensive clinical studies.%目的 研究一组Ⅲb及Ⅲc期结肠癌术后患者,在辅
Ⅲb及Ⅲc期结肠癌辅助化疗后行卡培他滨巩固化疗的临床研究
